### **Supplementary Materials**

Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, Sears D, and Lo NC. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. 2022.

### Contents

Technical Appendix	
Tables	7
Figures	11

### **Technical Appendix**

In this technical appendix, we provide further description of the study design and environment, data, model structure, and statistical analysis.

SARS-CoV-2 testing, quarantine, and isolation practices within the California state prisons Testing practices for SARS-CoV-2 varied over time within the California state prison system. The majority of tests were polymerase chain reaction (PCR). Residents were tested both reactively, if residents were symptomatic or were considered close contacts of a confirmed COVID-19 case, and systematically (weekly) during periods of high transmission. Following a positive test, most residents were not tested for the following 90 days. The distributions for the number of tests received by residents in the study population and the time between tests over the study period are shown in Figure A1.



Figure A1: Distribution of the number of tests and time between tests taken in the study population over the study period.

When residents received a positive SARS-CoV-2 test result, they were moved into isolation for 10-14 days. Isolation included single cell occupancy (provided there was sufficient such housing within the prison) or group isolation with other residents with active SARS-CoV-2 infection. Residents generally remained in their assigned housing while their SARS-CoV-2 test results were pending unless they were symptomatic.

#### Additional methodology for SARS-CoV-2 testing data

We excluded any false positive or inconclusive test results from the data (0.5% of tests). Often multiple tests were collected from residents on the same day. If multiple SARS-CoV-2 tests were collected from a resident on the same day with conflicting results (0.1% of tests), we excluded all tests from that day if: 1) the type of any test collected was unknown; or 2) the resident received multiple SARS-CoV-2 PCR tests with conflicting results. If a resident received both a SARS-CoV-2 antigen test and a SARS-CoV-2 PCR test on the same day with conflicting results, we excluded the result from the antigen test.

Additional methodology for COVID-19 index case definition and infectious period We defined a SARS-CoV-2 infection as any conclusive positive SARS-CoV-2 test in a resident unless they had a prior infection in the preceding 90 days and no negative SARS-CoV-2 PCR test in the interim. We assumed a 5-day infectious period based on literature (20,29). We shortened the assumed 5-day infectious period for a COVID-19 index case if the resident had a negative rapid antigen test during the infectious period. We excluded index cases if the resident had a negative PCR test during the infectious period to mitigate potential bias due to delayed detection of cases.

#### Additional methodology for close contacts of COVID-19 index case

Close contacts were excluded if they had a prior SARS-CoV-2 infection in the 90 days leading up to the first exposure with the index case unless they had a negative PCR test in the interim. Close contacts were required to have a negative SARS-CoV-2 test within 2 days of first exposure to the index case and have follow up testing data between 3 days after first exposure and 14 after last exposure. If any close contact tested positive for SARS-CoV-2 within 2 days of the index case's first positive test, we excluded the index case to limit bias from misattribution of close contacts. We defined secondary SARS-CoV-2 infections as close contacts who tested positive for SARS-CoV-2 during the follow up period.

Given residents were frequently moved, including for isolation, we plotted the number of days of close contact with the index case during their infectious period for the study period. The distribution of the time is shown in Figure A1.



Figure A2: Distribution of the number of days of contact between the index case during their infectious period and the close contact

#### Matching

We used the *MatchIt* package (32) to perform 1:10 matching of unvaccinated index cases to vaccinated cases. We calculated pairwise time differences (in days) between index cases to create a distance matrix and matched cases exactly by institution and by time (within 30 days). The distribution of the number of vaccinated index case matches for unvaccinated index cases is shown in the histogram in Figure A3, and the distribution of the distance between matches is shown in Figure A4. Each observation was weighted based on the number of matches.



Figure A3: Distribution of the number of vaccinated index case matches for unvaccinated index cases



Figure A4: Distribution of the distance based on time between matched index cases that were unvaccinated and vaccinated in the study

#### Pre-analysis plan

The pre-analysis plan is publicly available (31). The final analysis had minor deviations from the initial plan. We removed the random effects for each index case since the final dataset did not include repeated measures data (<1% of dataset, which was removed). We removed the inclusion criteria that index cases must have a negative PCR SARS-CoV-2 test in the 8 days prior to first positive test, in order to achieve an adequate sample size. This change would not be expected to have differential implications for eligibility of index cases who were vaccinated and unvaccinated. We increased the number of matches to 1:10 to maximize sample size.

#### Sensitivity analyses

We conducted several sensitivity analyses to assess robustness of study findings as outlined below.

Alternative COVID-19 vaccination status in index cases and contacts

In the primary analysis, we defined prior vaccination in the index case as a binary variable, where index cases were considered previously vaccinated if they received any dose of a COVID-19 vaccine at least 14 days prior to their first positive test. We conducted a sensitivity analysis where we defined COVID-19 vaccination status in index cases as the number of vaccine doses received at least 14 days prior to first positive test. We also conducted the regression analysis when aggregating close contact COVID-19 vaccination status to a binary variable representing any prior vaccination (Table S3).

#### Interaction between prior vaccination and natural infection

We assessed for a statistical interaction in the primary analysis between vaccination and prior natural infection in index cases. The remainder of the statistical specifications remained unchanged (Table S4).

#### Time since most recent vaccination or natural infection

We estimated the unadjusted attack rate of infection among vaccinated index cases, stratified by time since most recent COVID-19 vaccination (Figure S2). We performed three additional regression analyses to evaluate whether time since last vaccine, time since last infection, or time since last vaccine or infection had a relationship with the infectiousness of a SARS-CoV-2 infection. In these analyses, the coefficient of interest was the index case's time since most recent vaccination or natural infection. The remainder of the analyses remained the same, controlling for all pre-specified covariates in the main analysis (Table S5).

#### Alternative matching

We repeated the primary analysis under different matching specifications: 1) 1:10 matching by institution and time (within 15 days); and 2) 1:4 matching by institution and time (within 30 days). We repeated the analysis without matching, estimating robust errors instead of cluster-robust errors in the Poisson regression model (Table S6 and Figure S3).

#### Alternative infectious period

We tested the impact of varying assumptions about the start and duration of the infectious period on study outcomes, maintaining all other inclusion and exclusion criteria of the study. In these sensitivity analyses, we assumed the infectious period began 2 days prior to an index case's first positive test and had a duration of 1) 5 days and 2) 7 days (Table S7 and Figure S4).

#### Alternative regression model

We performed the primary analysis using a logistic regression model instead of a robust Poisson model, incorporating weights from matching as well as cluster-robust standard errors based on matching group membership. We report the odds ratios of infection given prior vaccination or prior infection and 95% confidence intervals (Table S8).

### Tables

Table S1: Unadjusted estimates of the attack rate of SARS-CoV-2 infection among close contacts of index cases by COVID-19 vaccination and SARS-CoV-2 infection history in index cases

Attack rate (%) (95% CI)	No prior vaccination	Prior vaccination
No prior infection	38.7 (31.9, 46.1)	29.8 (26.2, 33.6)
Prior infection	29.4 (20.3, 40.4)	21.9 (17.9, 26.5)

### Table S2: Primary analysis of the relationship of COVID-19 vaccination and prior SARS-CoV-2 infection on infectiousness of Omicron SARS-CoV-2 infections

		Relative % change in attack rate of infection in close contact (95% CI)
Index case	Prior vaccination only	-24.3 (-37.1, -8.8)
	Prior infection only	-21.7 (-36.4, -3.6)
Close contact	Number of vaccine doses	
	1 dose	1.2 (-8.1, 11.4)
	2 doses	2.3 (-15.6, 24.1)
	≥3 doses	3.5 (-22.5, 38.2)
	Prior infection only	-16.9 (-33, 3.1)
Institution	SARS-CoV-2 incidence in the 7 days	
	preceding the positive test in the index case	
	(natural log scale)	10.6 (-3.4, 26.6)

The primary analysis estimated the relationship of the index cases' vaccine status and prior natural infection history on attack risk of SARS-CoV-2 infection in the close contact. We adjusted for potential confounders, including the number of COVID-19 vaccine doses and prior natural infection history in close contacts as well as institution SARS-CoV-2 incidence and fixed effects.

	COVID-19 vaccination status	Relative % change in attack rate of infection in close contact (95% CI)
Index case	Prior vaccination	-24.3 (-37.1, -8.8)
	Number of vaccine doses	
	1 dose	-11.9 (-17.3, -6.2)
	2 doses	-22.5 (-31.7, -12)
	≥3 doses	-31.7 (-43.5, -17.5)
	Prior vaccination or infection	-30.2 (-43, -14.6)
Close contact	Prior vaccination	3.2 (-20.5, 34)
	Number of vaccine doses	
	1 dose	1.2 (-8.1, 11.4)
	2 doses	2.3 (-15.6, 24.1)
	≥3 doses	3.5 (-22.5, 38.2)
	Prior vaccination or infection	-9.2 (-32.5, 22.2)

# Table S3: Sensitivity analyses testing alternative definitions of COVID-19 vaccination status in index cases and close contacts on the infectiousness of Omicron SARS-CoV-2 infections

This sensitivity analysis represents distinct regression analyses measuring the infectiousness of SARS-CoV-2 infections in index cases among close contacts under different definitions of COVID-19 vaccine status in the index case and close contact. The sensitivity analysis was conducted by starting with the primary model and making a single change to either the index case or close contact's vaccine status under three definitions: (1) any vaccination as a binary variable; (2) vaccination as number of doses; (3) combined any vaccination and/or prior infection as binary definition.

# Table S4: Assessment of statistical interaction between COVID-19 vaccination and prior SARS-CoV-2 infection in the index case on the infectiousness of Omicron SARS-CoV-2 infections

	Relative % change in attack rate of infection in close contact (95% CI)	
Index case	Without interaction term	With interaction term
Prior vaccination	-24.3 (-37.1, -8.8)	-25.9 (-40.7, -7.4)
Prior infection	-21.7 (-36.4, -3.6)	-26.2 (-49.5, 7.9)
Interaction between vaccination and prior infection		8.3 (-31.6, 71.6)

# Table S5: Estimating the relationship between time since most recent COVID-19 vaccine dose or natural infection on infectiousness of Omicron SARS-CoV-2 infections

	Relative % change in attack rate of	
	infection in close contact (95% CI)	
Time since last COVID-19 vaccine dose (per 5 weeks)	6 (2, 10.2)	
Time since most recent SARS-CoV-2 infection (per 5 weeks)	5 (-2.7, 13.4)	
Time since most recent vaccine or infection (per 5 weeks)	4.5 (1.7, 7.4)	

We conducted three regression analyses estimating the relationship between: 1) time since most recent vaccination and risk of transmission of infection; 2) time since most recent infection and risk of transmission of infection; 3) time since most recent vaccination or infection and risk of transmission of infection. All analyses were adjusted for prior vaccination and/or infection in the index case as well as close contact and institution-specific characteristics.

# Table S6: Sensitivity analysis testing alternative matching specifications for primary analysis on the infectiousness of Omicron SARS-CoV-2 infections

		Relative % change in attack rate of infection in close contact
Matching specification	Index case	(95% CI)
1:10 matching of index cases by	Prior vaccination	-22.2 (-35.3, -6.4)
institution and within 15 days	Prior infection	-23.2 (-37.8, -5.2)
1:4 matching of index cases by	Prior vaccination	-22.5 (-35.7, -6.7)
institution and within 30 days	Prior infection	-21.8 (-36.7, -3.3)
No matching	Prior vaccination	-25.1 (-37.9, -9.8)
	Prior infection	-23 (-37.4, -5.4)

# Table S7: Sensitivity analysis testing alternative definition of infectious period in index case for primary analysis on the infectiousness of Omicron SARS-CoV-2 infections

		Relative % change in attack
		rate of infection in close
Infectious period	Index case	contact (95% CI)
Begins 2 days prior to first positive test, duration of 5 days	Prior vaccination	-18.1 (-31.3, -2.5)
	Prior infection	-15.9 (-31.8, 3.6)
Begins 2 days prior to first positive test, duration of 7 days	Prior vaccination	-17.9 (-31.2, -2)
	Prior infection	-14.8 (-30.7, 4.6)

# Table S8: Primary analysis using logistic regression model to evaluate the infectiousness of Omicron SARS-CoV-2 infections

Index case	Odds ratio of infection in close contact (95% CI)
Prior vaccination	0.65 (0.48, 0.88)
Prior infection	0.7 (0.52, 0.95)

Note: The primary analysis used a robust Poisson regression model, while this sensitivity analysis used a logistic regression model.

	Fraction of transmission from SARS-CoV-2 infections (%) (95% CI)		
			Among Omicron SARS-CoV-2 infections
	Within secondary cases	Among all Omicron	with complete prior
	in study population	SARS-COV-2 Infections	infection instory
No prior vaccination or infection	20.4 (16.5, 25)	23.9 (20.3, 27.8)	15.1 (12.5, 18)
Prior vaccination only	50.4 (45.2, 55.7)	52.2 (50.5, 53.6)	47.7 (47.3, 47.7)
Prior infection only	6.9 (4.6, 10.1)	4.6 (4.3, 4.8)	6.8 (6.6, 6.9)
Both prior vaccination and infection	22.3 (18.2, 27)	19.3 (17.4, 21.3)	30.5 (28.1, 32.8)

 Table S9: Estimation of the fraction of secondary transmission attributable to Omicron SARS-CoV-2 infections stratified by prior COVID-19 vaccination and natural infection history

We estimated the attributable fraction of transmission from SARS-CoV-2 infection among secondary cases, stratified by different vaccine and immune statuses of the index case. We performed this analysis under three circumstances: (1) study population; (2) among all confirmed SARS-CoV-2 infections in the study period; and (3) among confirmed SARS-CoV-2 infections in residents that were incarcerated before April 2020 due to underreporting of prior infection history. Further Methods description is available in the main text.

### Figures



**Figure S1: Study population flow chart.** We obtained data on residents incarcerated in the California state prison system from March 1, 2020, to May 20, 2022, who were diagnosed with COVID-19 based on a positive molecular test. We applied the inclusion and exclusion criteria to the index case of COVID-19 and the close contact who shared a cell for at least one night. The sample size at each step is plotted in the figure.



**Figure S2: Unadjusted estimates of the attack rate of Omicron SARS-CoV-2 infection of vaccinated index cases by time since the index cases' most recent vaccine dose.** We plotted the unadjusted attack rate and 95% binomial confidence intervals for vaccinated index cases, stratified by time (in weeks) since the index cases' most recent vaccine dose prior to first positive SARS-CoV-2 test. The adjusted estimates from the regression model are available in Table S6.



**Figure S3: Comparison of the unadjusted estimates of the attack rate of Omicron COVID-19 index cases under different matching specifications.** In the main analysis, we performed 1:10 matching of unvaccinated index cases to vaccinated index cases by institution and time (within 30 days). Here, we estimated the unadjusted risk of transmission of SARS-CoV-2 infection from index cases to close contacts under 3 alternative matching specifications: 1) 1:10 matching by institution and within 15 days, 2) 1:4 matching by institution and within 30 days, and 3) no matching, stratified by history of COVID-19 vaccination and/or natural SARS-CoV-2 infection in index cases.



**Figure S4: Comparison of the unadjusted estimates of the attack rate of Omicron COVID-19 index cases in the primary analysis and under various definitions of the infectious period.** In the main analysis, we assumed residents were infectious beginning the day of the collection of their first positive test for 5 days. We varied the definition of the infectious period in sensitivity analysis and estimated the unadjusted risk of transmission of SARS-CoV-2 infection from index cases to close contacts under 2 alternate definitions of the infectious period: 1) duration of 5 days, beginning 2 days prior to first positive test and 2) duration of 7 days, beginning 2 days prior to first positive test. We plotted the attack rates of index cases stratified by history of COVID-19 vaccination and/or natural SARS-CoV-2 infection.



**Figure S5: Omicron SARS-CoV-2 infections included as index cases by institution**. We plotted the absolute number of index cases included in the analysis by institution (dark blue) with y-axis on left. We plotted the proportion of total Omicron SARS-CoV-2 infections included as index cases by institution (light blue) with y-axis on right. Infections from some institutions are overrepresented in our final sample due to our strict inclusion and exclusion criteria established to address confounding and misattribution concerns.